Valuation Thiogenesis Therapeutics, Corp. OTC Markets
Stocks
TTIPF
CA88410L1022
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
14:30:19 07/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.4200 USD | +7.69% |
|
0.00% | -28.01% |
Company Valuation: Thiogenesis Therapeutics, Corp.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Market Cap 1 | 22.54 | 33.43 | 27.61 | 33.69 |
| Change | - | 48.3% | -17.4% | 22.03% |
| Enterprise Value (EV) 1 | 16.34 | 26.35 | 23.76 | 32.08 |
| Change | - | 61.23% | -9.83% | 34.99% |
| P/E | -3.74x | -5.8x | -8.65x | -4.25x |
| PBR | 3.77x | 6.04x | 8.06x | 58.7x |
| PEG | -0x | 0.3x | 0.2x | -0x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / EBIT | -8.14x | -5.06x | -6.64x | -4.34x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 3 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 3 | -0.1552 | -0.1294 | -0.0693 | -0.1528 |
| Distribution rate | - | - | - | - |
| Net sales | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -2.009 | -5.206 | -3.579 | -7.395 |
| Net income 1 | -3.924 | -5.063 | -3.146 | -7.426 |
| Net Debt 1 | -6.196 | -7.076 | -3.848 | -1.616 |
| Reference price 3 | 0.5800 | 0.7500 | 0.6000 | 0.6500 |
| Nbr of stocks (in thousands) | 38,862 | 44,571 | 46,017 | 51,836 |
| Announcement Date | 28/04/23 | 29/04/24 | 25/04/25 | 30/04/26 |
1CAD in Million2USD in Million3CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 34.4x | 6.13x | 18.24x | 0.93% | 51.22B | ||
| -21.71x | 301.09x | -22.35x | -.--% | 45.38B | ||
| 48.36x | 5.61x | 30.68x | -.--% | 41.97B | ||
| 32.97x | 3.21x | 13.87x | -.--% | 42.15B | ||
| 29.48x | 8.52x | 21.54x | 0.39% | 31.95B | ||
| 34.84x | 5.71x | 25.97x | -.--% | 17.1B | ||
| 24.28x | 2.11x | 9.12x | 1.11% | 14.76B | ||
| 77.97x | 4.1x | 15.89x | -.--% | 13.91B | ||
| Average | 32.57x | 42.06x | 14.12x | 0.3% | 32.31B | |
| Weighted average by Cap. | 27.77x | 57.29x | 12.69x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TTI Stock
- TTIPF Stock
- Valuation Thiogenesis Therapeutics, Corp.
Select your edition
All financial news and data tailored to specific country editions
















